Phenocopies of primary immunodeficiency: Difference between revisions
Jump to navigation
Jump to search
Line 28: | Line 28: | ||
{{Family tree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}} | {{Family tree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}} | ||
{{Family tree/end}} | {{Family tree/end}} | ||
==ALPS-SFAS== | |||
*Heritable disorder of apoptosis, resulting in the accumulation of autoreactive lymphocytes. | |||
*Manifests in early childhood as nonmalignant lymphadenopathy with hepatosplenomegaly and autoimmune cytopenias. | |||
*Patients with mutations have developed B and T-cell lymphomas. | |||
*Peripheral blood analysis in patients has demonstrated hypergammaglobulinemia along with increased numbers of B and T lymphocytes. | |||
*Some studies have demonstrated that ALPS is compatible with long-term survival. | |||
===Types of mutation=== | |||
*Type IA is caused by heterozygous mutation in the FAS gene (TNFRSF6, or CD95) | |||
*Type Ib is caused by heterozygous mutation in the FAS ligand (FASL) gene (TNFSF6 or CD95L) | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 15:04, 19 October 2018
Immunodeficiency Main Page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2], Anmol Pitliya, M.B.B.S. M.D.[3]
Overview
Classification
Phenocopies of PID | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Associated with Somatic Mutations | Associated with Auto-Antibodies | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ALPS-SFAS | Chronic mucocutaneous candidiasis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RALD(RAS-associated autoimmune leukoproliferative disease) | Adult-onset immunodeficiency with susceptibility to mycobacteria | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cryopyrinopathy(Muckle-Wells Syndrome) | Recurrentt skin infections | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hypereosinophilic syndrome due to somatic mutations in STAT5b | Pulmonary alveolar proteinosis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquired angiooedema | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Atypical Hemolytic Uremic Syndrome | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Thymoma with hypogammaglobulinemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ALPS-SFAS
- Heritable disorder of apoptosis, resulting in the accumulation of autoreactive lymphocytes.
- Manifests in early childhood as nonmalignant lymphadenopathy with hepatosplenomegaly and autoimmune cytopenias.
- Patients with mutations have developed B and T-cell lymphomas.
- Peripheral blood analysis in patients has demonstrated hypergammaglobulinemia along with increased numbers of B and T lymphocytes.
- Some studies have demonstrated that ALPS is compatible with long-term survival.
Types of mutation
- Type IA is caused by heterozygous mutation in the FAS gene (TNFRSF6, or CD95)
- Type Ib is caused by heterozygous mutation in the FAS ligand (FASL) gene (TNFSF6 or CD95L)